High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma

Stanford University

Status and phase: Completed; Phase 2

Conditions: Blood and Marrow Transplant (BMT); Lymphomas: Non-Hodgkin; Lymphoma, Non-Hodgkin

Treatments: Procedure: ablative allogeneic hematopoietic cell transplantation

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00186394

NCT00186394

76679

BMT4L

Details and patient eligibility

About

To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.

Full description

To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by following clinical outcomes and quality of life measures; and evaluate graft versus host disease incidence and severity with regimen.

Enrollment: 35 estimated patients

Sex: All

Ages: 18 to 61 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Morphologically confirmed relapsed non-Hodgkin's lymphoma

Age: >18 and <61 years of age

Signed informed consent Exclusion Criteria:Hepatic dysfunction defined by serum transaminases >2.5X normal values

Serum creatinine of > 2 mg/dl or creatinine clearance < 60 ml/min

Diseases other than non-Hodgkin's lymphoma

Prior bone marrow transplant procedure

Severe psychological or medical illness

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)